Akoya Biosciences, Inc.
AKYA
$1.16
$0.021.75%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 16.64M | 21.34M | 18.81M | 23.16M | 18.35M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 16.64M | 21.34M | 18.81M | 23.16M | 18.35M |
| Cost of Revenue | 6.77M | 6.96M | 7.09M | 9.78M | 9.97M |
| Gross Profit | 9.87M | 14.39M | 11.72M | 13.39M | 8.38M |
| SG&A Expenses | 17.58M | 15.69M | 14.67M | 19.09M | 19.86M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 29.91M | 27.07M | 26.24M | 34.16M | 35.39M |
| Operating Income | -13.27M | -5.73M | -7.42M | -11.00M | -17.04M |
| Income Before Tax | -15.60M | -8.21M | -10.49M | -13.10M | -23.42M |
| Income Tax Expenses | 48.00K | -8.00K | 44.00K | 47.00K | 63.00K |
| Earnings from Continuing Operations | -15.65M | -8.20M | -10.53M | -13.15M | -23.48M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -15.65M | -8.20M | -10.53M | -13.15M | -23.48M |
| EBIT | -13.27M | -5.73M | -7.42M | -11.00M | -17.04M |
| EBITDA | -11.47M | -3.88M | -5.60M | -9.07M | -14.99M |
| EPS Basic | -0.32 | -0.17 | -0.21 | -0.27 | -0.48 |
| Normalized Basic EPS | -0.19 | -0.12 | -0.12 | -0.16 | -0.24 |
| EPS Diluted | -0.32 | -0.17 | -0.21 | -0.27 | -0.48 |
| Normalized Diluted EPS | -0.19 | -0.12 | -0.12 | -0.16 | -0.24 |
| Average Basic Shares Outstanding | 49.66M | 49.56M | 49.50M | 49.42M | 49.19M |
| Average Diluted Shares Outstanding | 49.66M | 49.56M | 49.50M | 49.42M | 49.19M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |